Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Experts Say Qazkom too Big to Fail
BY YERBOLAT UATKHANOV in BUSINESS on 6 JANUARY 2017
ASTANA – Experts consider the situation with Qazkom shows the complex situation in the Kazakh financial field, but predict the bank is stable and too important a financial institution for the state and won’t have really serious problems.
“Qazkom has already been promised that it will get support at the highest level. This is a signal to creditors that they don’t need to worry. The bank has a significant loan portfolio in foreign currency and in tenge,” said economist Sayan Kombarov, according to forbes.kz.
The state does not give a negative scenario and doesn’t even want to think about Qazkom’s falling, added economist Zharas Akhmetov.
“And what if there is no other way out? It is too big to allow it to fail,” he said.
“I think that bank lending and the financial system led by the National Bank, as well as the monetary and economic policy led by the government, slow down long-term sustainable development of the country,” said Kombarov.
“Banking and foreign loans, which are attracted to private and quasi-public sectors, do not lead to an increase in productivity and responsible and profitable investment,” he added.
Kombarov noted in the case of Qazkom’s collapse, the Kazakh market would have had serious problems and fall in depositors’ confidence.
“Banks with partial redundancy can never return all deposits at the same time. In this case, other banks may fall. In this case, depositors can lose their money or National Bank will have to assist other banks at the expense of emissions that can lead to depreciation of the tenge, reducing the borrowing ratings of second tier banks,” he added.
Kombarov is a strong supporter of the idea that private or public banks or businesses generating losses should not be maintained at the expense of the state and taxpayers.
“Loss-making and unprofitable enterprises and their managements do not bear any responsibility for society. Instead of this, they get more help at the expense of budget funds and taxpayers. Foreign creditors are willing to lend under the state guarantees, which brings losses on the shoulders of the productive and responsible savers who are forced to bear the burden of the worsening economic and social situation. Savings are used for the support of unproductive and parasitic structures,” he said.
He does not see an optimal solution in the situation with Qazkom.
“Management of the bank and financial regulators are responsible for the fact that problems weren’t solved in time. A default of unprofitable enterprises would be the best solution that enables to clean rottenness from the financial system, as long as it does not spread. It is necessary to organise the market correction, sale of illiquid assets at market price and debt restructuring. After the market correction and the definition of actual prices for assets, the growth is possible,” said Kombarov.
Freedom Finance Director Timur Turlov noted the process of restructuring bank debts will be continued this year, reported kursiv.kz. He added an alliance of Qazkom and Halyk Bank, rumoured late last year, is still possible.
National Bank provided a 400.8 billion tenge ($US1.22 billion) loan for Qazkom on Dec. 14. A partial repayment of 200 billion tenge ($US600 million) was made Dec. 26.
Bloomberg reported earlier that the salvation of Qazkom may cost 1.5 trillion tenge ($4.5 billion). The bank rescue is one of the alternatives being discussed by representatives of Qazkom and National Bank. The problem could become the largest since the global financial crisis, which occurred seven years ago when the state provided $20 billion to restructure the debt of Kazakhstan domestic banks.
Someone has been quietly loading this.
Guess u changed your mind lol. This could get interesting.
MEDA
.10's gone
10mill O/S
Someone painting the ask for 272 shares, really isn't that incredible.
Updated today, back to active
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=ZYaIV7xaX6zao09gBDZtEg%253d%253d&nt7=0
Thanks for the update, that's great news!
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
Nov 14, 2016
OTC Disclosure & News Service
-
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
The Treatment Success of ViaDerma's Proprietary Delivery System for Several Diseases by the Efficient and Effective Transdermal Delivery of CBD's & THC to the Localized Treatment Area & into the Blood Stream
LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.
On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.
ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
Market for the following Drugs:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem™, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit: www.viadermalicensing.com.
Forward-Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Contact information:
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Phone: 310-496-5744
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
The Company evaluated all material events and transactions that occurred after September 30, 2016 through November 14, 2016, the date these financial statements were available to be issued. During this period the Company did not have any material recognizable subsequent events, except as described below.
On November 7, 2016, Mr. Turlov made a $70,000 capital contribution to the Company.
I think everyone here likes it lol. Hopefully the trading stays the same here, for us all.
You might be on to something, it's really starting to look like Perkins is buying shares. I got in a little over 2 weeks ago and since I've been in, it's almost all buys on the ask and no selling at bid. I wish all my stocks traded like EXAI.
More filings out today...
http://www.otcmarkets.com/stock/DEQI/filings
2.2 mill volume in the first 45 minutes
"The guru of ganja"
http://www.edrosenthal.com
Great find!
$DEQI
I'm a shareholder here even though I don't post, and I can also confirm what Dina is saying.
Seems they are on NACS Expo in Atlanta in October:
http://www.otcmarkets.com/companyPresentationViewer?cmdId=1580&symbol=RCIT
http://www.nacsonline.com/nacsshow/Pages/default.aspx
Yesterday, Reelcause was in one of the 3 largest Korean newspapers:
https://www.facebook.com/1669431223383431/photos/a.1670909739902246.1073741827.1669431223383431/1706968736296346/?type=3&theater
And a shorter article online:
http://www.koreadaily.com/news/read.asp?page=1&branch=LA&source=LA&category=society.people&art_id=4650614
$FOUR
Video ABCnews:
http://abcnews.go.com/WNT/video/major-league-player-baseball-pitcher-wear-hat-24273265
Shops and Partnerships:
http://www.wilson.com/en-us/fastpitch/protective-gear/catcher/promotion-fastpitch-chest-protector
http://www.dickssportinggoods.com/search/index.jsp?kwCatId=&kw=isoblox&origkw=isoblox&sr=1
http://www.stx.com/mens/gear/protection/cell-ii-arm-pads
http://www.tk-hockey.com/tk-latest-news/new-technologies-goalkeepers/
$FOUR 14m o/s, 3m float
Video about Wilson and Isoblox:
Video about Wilson and Isoblox:
In June someone bought 40K worth of shares at .031-.06.
FOUR 24.06.2016 0,0350 0,0600 0,0310 0,0310 712.694
https://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=45605&i=FOUR&pv=stock-chart&puv=110794#&&vs=636095495513412448
$FOUR
Thanks Pete! I have a better dd post from earlier today, if u want to see some good links on FOUR.
FOUR, .0035, 14m O/s, 3m float, 40m a/s, market cap $49k, down on low volume
About Isoblox:
THE SCIENCE OF PROTECTION
isoBLOX™ is a recent breakthrough development unlike anything in the field of impact protection. Engineered and lab tested to offer exceptional impact resistance without compromising flexibility or adding bulk. Its bio-mechanical design is highly breathable and creates moving, form-fitting protection.
isoBLOX™ impact diffusing technology uses a patented inter-connected shock plate system to deliver superior impact resistance. Inner skeletal plates move with the body for the ultimate in flexible protection. isoBLOX™ makes products stronger, thinner and more flexible.
Pinwrest Development Group develops, source-manufactures and distributes products for retail under the isoBLOX™ brand and technology.
MLB approved and patented technology, partnerships with Wilson and STX (Products are under Wilson and STX brand and use Isoblox patented technology, it´s always in the description)
Wilson $1b company, products with Isoblox patented technology
Video about Wilson and Isoblox:
FOUR, .0035, 14m O/s, 3m float, 40m a/s, market cap $49k, down on low volume
About Isoblox:
THE SCIENCE OF PROTECTION
isoBLOX™ is a recent breakthrough development unlike anything in the field of impact protection. Engineered and lab tested to offer exceptional impact resistance without compromising flexibility or adding bulk. Its bio-mechanical design is highly breathable and creates moving, form-fitting protection.
isoBLOX™ impact diffusing technology uses a patented inter-connected shock plate system to deliver superior impact resistance. Inner skeletal plates move with the body for the ultimate in flexible protection. isoBLOX™ makes products stronger, thinner and more flexible.
Pinwrest Development Group develops, source-manufactures and distributes products for retail under the isoBLOX™ brand and technology.
MLB approved and patented technology, partnerships with Wilson and STX (Products are under Wilson and STX brand and use Isoblox patented technology, it´s always in the description)
Wilson $1b company, products with Isoblox patented technology
Video about Wilson and Isoblox:
FOUR, .0035, 14m O/s, 3m float, 40m a/s, market cap $49k, down on low volume
About Isoblox:
THE SCIENCE OF PROTECTION
isoBLOX™ is a recent breakthrough development unlike anything in the field of impact protection. Engineered and lab tested to offer exceptional impact resistance without compromising flexibility or adding bulk. Its bio-mechanical design is highly breathable and creates moving, form-fitting protection.
isoBLOX™ impact diffusing technology uses a patented inter-connected shock plate system to deliver superior impact resistance. Inner skeletal plates move with the body for the ultimate in flexible protection. isoBLOX™ makes products stronger, thinner and more flexible.
Pinwrest Development Group develops, source-manufactures and distributes products for retail under the isoBLOX™ brand and technology.
MLB approved and patented technology, partnerships with Wilson and STX (Products are under Wilson and STX brand and use Isoblox patented technology, it´s always in the description)
Wilson $1b company, products with Isoblox patented technology
Video about Wilson and Isoblox:
No prob Pollo, I agree, I think we here something soon. By the way, I do see RCIT on bob, good catch.